Funded Startups in Pennsylvania
Disclosed funding in Pennsylvania is concentrated at the top: the largest disclosed round is Mineralys Therapeutics at $500M (2026-06-03), which dwarfs the…
Disclosed funding in Pennsylvania is concentrated at the top: the largest disclosed round is Mineralys Therapeutics at $500M (2026-06-03), which dwarfs the next-largest disclosed amount at $250M from ArriVent Biopharma (2026-05-11). Even outside that peak, five of the 35 disclosed rounds are at or above $100M, while 25 disclosed rounds are at or above $1M, showing a long tail of smaller checks.
The list also clusters geographically and temporally. Philadelphia accounts for 16 of the 50 entries, far more than Pittsburgh’s 10 and Wayne’s 3, and those concentrations include large biotech rounds like Alterra IOS ($244M, 2026-06-05) and Cabaletta Bio ($150M, 2026-05-04). Dates span 2026-04-23 to 2026-08-11 with entries in every shown year bucket (2026), while stage labeling skews to “Series Unknown” (37 of 50), with smaller counts in Seed (6), Pre-Seed (4), Series D (2), and Series A (1).
Most recent rounds
50 of 601551 more funded startups
This page shows the 50 most recent rounds (back to Apr 2026). The full 601-company history for this listing opens on a FundedIQ plan.
Unlock all 601 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which disclosed round is the clear outlier, and what sits just below it?
Mineralys Therapeutics’ $500M (2026-06-03) is the outlier on disclosed size, with the next-largest disclosed amount far lower at $250M from ArriVent Biopharma (2026-05-11). The remaining high disclosed checks—$244M (Alterra IOS, 2026-06-05), $150M (Cabaletta Bio, 2026-05-04), and $115M (Ocugen, 2026-05-04)—stay well below the $250M band.
Do any cities dominate the geography of these funded startups?
Philadelphia is the dominant city in the listing with 16 entries, including Fore Biotherapeutics (2026-07-07, $67M) and multiple large biotech/AI names such as Alterra IOS ($244M, 2026-06-05) and Datavault AI ($60M, 2026-05-03). Pittsburgh follows with 10 entries (e.g., Gecko Robotics, 2026-08-11, $100K; Gray Swan, 2026-05-28, $40M), while Wayne has 3 entries (Stephano Slack LLC, undisclosed; Verdafresh, undisclosed; Cagent Vascular, 2026-05-19, $41M).
Is the stage mix dominated by a single label?
Yes. “Series Unknown” appears on 37 of 50 rows, while Seed accounts for 6 and Pre-Seed for 4; Series D is 2 and Series A is 1. That pattern is visible alongside late-stage markers like Fore Biotherapeutics (Series D, 2026-07-07, $67M) versus early-stage labels such as Agni Semiconductor (Seed, 2026-06-15, $5M) and Neuraville (Pre-Seed, 2026-05-18, $140K).
How does the list look from a sector standpoint—are there repeated themes?
Biotechnology is the most repeated sector with 11 entries, including Mineralys Therapeutics ($500M, 2026-06-03) and multiple other biotech financings like ArriVent Biopharma ($250M, 2026-05-11) and Ocugen ($115M, 2026-05-04). Financial Services has 7 entries and AI has 6, with examples such as Gray Swan (AI, Series A, 2026-05-28, $40M) and Datavault AI (AI, 2026-05-03, $60M).
What is the funding-size distribution like for disclosed rounds, and what does it imply for deal screening?
For disclosed rounds, 5 reach at least $100M and 7 reach at least $50M, while 15 are at least $10M and 25 are at least $1M. This means screening is likely to encounter many sub-$10M outcomes alongside a smaller number of very large financings, such as Fore Biotherapeutics ($67M, 2026-07-07) versus the minimum disclosed $10K at ATV Traction (2026-04-23).
Know who just raised. Then know who to call.
Every newly funded startup with its round, its investors, and its founders — delivered weekly, or searchable back to 2020.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.